Molecular Taxonomy of Pediatric Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- B-cell Childhood Acute Lymphoblastic Leukemia
- Sponsor
- Children's Oncology Group
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Cellular origins of relapse and the underlying epigenetic mechanisms associated with drug resistance
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
This laboratory study is looking into genes in samples from younger patients with relapsed acute lymphoblastic leukemia. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
Detailed Description
OBJECTIVES: I. To identify global changes in the epigenome and various underlying histone modifications that characterize relapsed acute lymphoblastic leukemia (ALL). II. To identify specific transcription factor-binding sites associated with histone alterations. III. To correlate gene expression changes of differentially regulated genes at relapse with underlying chromatin modifications. OUTLINE: Archived bone marrow samples, collected at the time of diagnosis and relapse, are analyzed for gene expression and histone modifications by microarray, chromatin immunoprecipitation (ChIP) sequencing, and quantitative real-time polymerase chain reaction (qRT-PCR).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of B-cell acute lymphoblastic leukemia
- •Paired diagnosis-relapse primary patient samples obtained from the Children's Oncology Group (COG) cell bank
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Cellular origins of relapse and the underlying epigenetic mechanisms associated with drug resistance
Time Frame: 1 month
Genes associated with histone modification
Time Frame: 1 month
Biological pathways involved in relapse
Time Frame: 1 month